Loading
Telo Genomics Corp. Stock: price and insider trades · Canada
Telo Genomics Corp.: what insiders have been doing
Telo Genomics Corp. is a Health Care company. Its directors and officers file their transactions with SEDI. In the past year (23 October 2025 to 23 October 2026), 9 filings came from 2 insiders.
The filings describe grants, exercises and other transfers rather than trades on the open market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
For context, the typical company on the same exchange (median of 2,471 companies) published 12 filings over the same period, against 9 filings here. The full history, which starts in 2019, counts 3 purchases against no sales.
Over the last twelve months, not one insider purchase of Telo Genomics Corp. stock was filed.
This summary is built from SEDI disclosures alone and does not predict where the share price will go.
Insider Decl.
31
Thresholds
n/a
Buy Volume
€20,637
3 ops. · all time
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended June 2025 · cache
CA$0.07
Analyst consensus
Income statement
EBITDA-CA$2.7M
Net income-CA$2.7M0.0% margin
Valuation
Beta0.11
Balance sheet & cash
Market capCA$7M
Total debtCA$32.5k
Free Cash Flow-CA$2.3M
Profitability & ownership
ROE-3055.8%
ROA-106.9%
% insiders3.0%
% institutions0.4%
Last declaration on 7 August 2026
Declarations31 total
1,000,000 sharesOptionsTSXSEDI:4761686
OptionsTSXSEDI:4761685
200,000 sharesWarrantsTSXSEDI:4761684
WarrantsTSXSEDI:4761683
Convertible DebenturesTSXSEDI:4761682
Convertible DebenturesTSXSEDI:4761681
500,000 sharesOptionsTSXSEDI:4759668
3,700,000 sharesOptionsTSXSEDI:4740412
OptionsTSXSEDI:4740411
80,000 shares@ CA$0.30100.0% of flowCommon SharesTSXSEDI:4092281
Canonical exit: 5 Jun 2023 (T+90)
Common SharesTSXSEDI:4043760
Common SharesTSXSEDI:3908664
274,510 shares@ CA$0.2043.5% of flowCommon SharesTSXSEDI:3825322
10,000 shares@ CA$0.50100.0% of flowCommon SharesTSXSEDI:3773016
50,000 shares@ CA$0.1514.1% of flowCommon SharesTSXSEDI:3713285
200,000 sharesCommon SharesTSXSEDI:3637862
20,000 shares@ CA$0.18Common SharesTSXSEDI:3619259
Canonical exit: 26 Jan 2021 (T+90)
Common SharesTSXSEDI:3619258
15,000 shares@ CA$0.19Common SharesTSXSEDI:3617479
Canonical exit: 19 Jan 2021 (T+90)
450,000 shares@ CA$0.1052.9% of flowCommon SharesTSXSEDI:3456634
400,000 shares@ CA$0.1047.1% of flowCommon SharesTSXSEDI:3456673
450,000 shares@ CA$0.10100.0% of flowCommon SharesTSXSEDI:3456830
274,510 shares@ CA$0.1021.4% of flowCommon SharesTSXSEDI:3456696
Common SharesTSXSEDI:3456628
450,000 shares@ CA$0.1035.1% of flowCommon SharesTSXSEDI:3456630
25 of 31 declarations
About Telo Genomics Corp.
Telo Genomics Corp. is a biotechnology company focused on developing diagnostic tests based on telomerase for cancer. It is listed on the XTSE.
